RT Journal Article
SR Electronic
T1 The neurophysiological brain-fingerprint of Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.03.23285441
DO 10.1101/2023.02.03.23285441
A1 da Silva Castanheira, Jason
A1 Wiesman, Alex I.
A1 Hansen, Justine Y.
A1 Misic, Bratislav
A1 Baillet, Sylvain
A1 ,
A1 ,
YR 2023
UL http://medrxiv.org/content/early/2023/12/01/2023.02.03.23285441.abstract
AB In this study, we investigate the clinical potential of brain-fingerprints derived from electrophysiological brain activity for diagnostics and progression monitoring of Parkinson’s disease (PD). We obtained brain-fingerprints from PD patients and age-matched healthy controls using short, task-free magnetoencephalographic recordings. The rhythmic components of the individual brain-fingerprint distinguished between patients and healthy participants with approximately 90% accuracy. The most prominent cortical features of the Parkinson’s brain-fingerprint mapped to polyrhythmic activity in unimodal sensorimotor regions. Leveraging these features, we also show that Parkinson’s disease stages can be decoded directly from cortical neurophysiological activity. Additionally, our study reveals that the cortical topography of the Parkinson’s brain-fingerprint aligns with that of neurotransmitter systems affected by the disease’s pathophysiology. We further demonstrate that the arrhythmic components of cortical activity are more variable over short periods of time in patients with Parkinson’s disease than in healthy controls, making individual differentiation between patients based on these features more challenging and explaining previous negative published results. Overall, we outline patient-specific rhythmic brain signaling features that provide insights into both the neurophysiological signature and clinical staging of Parkinson’s disease. For this reason, the proposed definition of a rhythmic brain-fingerprint of Parkinson’s disease may contribute to novel, refined approaches to patient stratification and to the improved identification and testing of therapeutic neurostimulation targets.Lay summary We propose a new method to help diagnose and monitor Parkinson’s disease (PD) using patients’ unique brain-fingerprint. These fingerprints are based on the brain’s electrical activity, which we measured without any specific tasks, using a technique called magnetoencephalography. Remarkably, we found that these brain-fingerprints can differentiate between people with Parkinson’s and those without, with about 90% accuracy. Specifically, we noticed that certain rhythmic patterns in the brain, particularly in areas involved in sensory and motor functions, were key indicators of Parkinson’s. Interestingly, these patterns also helped us identify the different stages of the disease.Additionally, our research shows that the arrangement of these brain-fingerprints in Parkinson’s patients corresponds to how the neurochemistry of the brain is impacted by the disease. We also observed that certain irregular patterns in the brain’s activity, which vary more from moment to moment in Parkinson’s patients, make it harder to distinguish between individuals based on these features alone. This finding sheds light on why previous studies reported challenges with similar approaches.Overall, our study offers new insights into the unique brain activity patterns in Parkinson’s disease and suggests that individual brain-fingerprints could be valuable in tailoring treatment plans and developing new therapies for this condition.Competing Interest StatementThe authors have declared no competing interest.Funding StatementData collection and sharing for this project was provided by the Quebec Parkinson Network (QPN), the Pre-symptomatic Evaluation of Novel or Experimental Treatments for Alzheimer's Disease (PREVENT-AD; release 6.0) program, and the Open MEG Archives (OMEGA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The QPN is funded by a grant from Fonds de recherche du Quebec - Sante (FRQS). PREVENT-AD was launched in 2011 as a $13.5 million, 7-year public-private partnership using funds provided by McGill University, the FRQS, an unrestricted research grant from Pfizer Canada, the Levesque Foundation, the Douglas Hospital Research Centre and Foundation, the Government of Canada, and the Canada Fund for Innovation. Private sector contributions are facilitated by the Development Office of the McGill University Faculty of Medicine and by the Douglas Hospital Research Centre Foundation (http://www.douglas.qc.ca/). OMEGA and the Brainstorm app are supported by funding to SB from the NIH (R01-EB026299), a Discovery grant from the Natural Science and Engineering Research Council of Canada (436355-13), the CIHR Canada research Chair in Neural Dynamics of Brain Systems, the Brain Canada Foundation with support from Health Canada, and the Innovative Ideas program from the Canada First Research Excellence Fund, awarded to McGill University for the HBHL initiative. This work was supported by a grant F32-NS119375 (AIW) from the National Institutes of Health and a doctoral fellowship from NSERC (JDSC, JYH).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at: The data are available through the Clinical Biospecimen Imaging and Genetic (C-BIG) repository (https://www.mcgill.ca/neuro/open-science/c-big-repository), the PREVENT-AD open resource (https://openpreventad.loris.ca/ and https://registeredpreventad.loris.ca), and the OMEGA repository (https://www.mcgill.ca/bic/resources/omega). Normative neurotransmitter density data are available from neuromaps (https://github.com/netneurolab/neuromaps).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data are available through the Clinical Biospecimen Imaging and Genetic (C-BIG) repository (https://www.mcgill.ca/neuro/open-science/c-big-repository)84, the PREVENT-AD open resource (https://openpreventad.loris.ca/ and https://registeredpreventad.loris.ca)85, and the OMEGA repository (https://www.mcgill.ca/bic/resources/omega)86. Normative neurotransmitter density data are available from neuromaps (https://github.com/netneurolab/neuromaps)36.